Evidence map›Paper›PMID 28480695›Full record

ArticleIranian biomedical journal2017

Expression Study and Clinical Correlations of MYC and CCAT2 in Breast Cancer Patients

Shaghayegh Sarrafzadeh, Lobat Geranpayeh, Behnoosh Tasharrofi, Mohammad Soudyab, Elahe Nikpayam, Mostafa Iranpour, Reza Mirfakhraie, Jalal Gharesouran, Somayyeh Ghafouri-Fard, Soudeh Ghafouri-Fard

Open access · diamondAbstract read
In one paragraph

Article in Iranian biomedical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Expression analysis of AFAP1-AS1 and AFAP1 in breast cancer.Cancer biomarkers : section A of Disease markers · 2018
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shaghayegh SarrafzadehDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Lobat GeranpayehDepartment of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Behnoosh TasharrofiDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad SoudyabDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Elahe NikpayamDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mostafa IranpourDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Reza MirfakhraieDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jalal GharesouranDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Somayyeh Ghafouri-FardDepartment of Community and Preventive Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Soudeh Ghafouri-FardDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colon cancer-associated transcript 2 (CCAT2) is a newly recognized lncRNA transcribed from the 8q24 genomic region. It functions as an oncogene in various types of cancers including breast cancer, in which it affects Wnt/β-catenin pathway. Previous studies have shown a putative interaction between this lncRNA and MYC proto-oncogene. Methods: In the current study, we evaluated the expression of CCAT2 in breast cancer tissues with regards to the expression of its target MYC. In addition, we assessed the relationship between CCAT2 and MYC expression levels in tumor tissues and the clinical prognostic characteristics of breast cancer patients. Results: MYC expression levels were significantly up-regulated in tumor tissues compared with adjacent non-cancerous tissues (ANCTs), while such analysis showed no statistically significant difference between these two tissue types in CCAT2 expression. Starkly increased CCAT2 gene expression levels were found in 12/48 (25%) of cancer tissue samples compared with their corresponding ANCTs. Furthermore, significant inverse correlations were found between CCAT2 expression and stage, as well as lymph node involvement. Besides, a significant inverse correlation was found between the relative MYC expression in tumor tissues compared with their corresponding ANCTs and disease stage. Conclusion: These results highlight the significance of MYC and CCAT2 expressions in the early stages of breast cancer development and suggest a potentially significant role for CCAT2 in a subset of breast cancer patients, which could be applied as a potential therapeutic target in these patients.

Indexed as

Breast cancerc-MYCLong non-coding RNA

Identifiers

PMID28480695
PMCPMC5548962
OpenAlexW2737231458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.